BEIJING, July 5, 2024 /PRNewswire/ — The “40th Anniversary, Discovery of Chengjiang Biota — International Palaeontological Forum” kicked off on July 2 in Chengjiang, Yuxi, Southwest China’s Yunnan Province, and will last to July 6.

This international forum aims to look back on the cooperation results in recent years, share experience, and look forward to the future. By leveraging the strengths of domestic and foreign research institutions, the forum seeks to deepen international cooperation in scientific research.

Experts and scholars from China, the United Kingdom, the United States, the Republic of Korea and Switzerland, have attended the forum. A total of 39 oral presentations and six academic posters will be presented to focus on domestic and foreign research achievements in life evolution in the early Cambrian Age.

Located on the shores of Fuxian Lake in the central part of Yunnan Province, the Chengjiang Biota is known as a “world-class treasure trove for fossils”. On July 1, 2012, the Chengjiang Biota was inscribed on the UNESCO World Heritage List, becoming China’s first and Asia’s only fossil world natural heritage site.

To date, more than 20 phyla and over 300 species of rare Cambrian fossils have been discovered in the Chengjiang Biota, with 80 percent of them being new species. The Chengjiang Fossil Site World Natural Heritage Museum now has a collection of over 60,000 specimens.

Original link: https://en.imsilkroad.com/p/340963.html

Source

HANGZHOU, China, July 5, 2024 /PRNewswire/ — Zhejiang Doer Biologics Co., Ltd. (“Doer Bio”), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that the company has completed the enrollment in the Phase 1b/2a trial evaluating DR10624 in obese subjects with modest hypertriglyceridemia in New Zealand. DR10624 is a first-in-class (FIC), long-acting tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon-like peptide-1 receptor (GLP-1R), and Glucagon receptor (GCGR).

The Phase 1b/2a study is a randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DR10624 in adult obese subjects (BMI of 30 to 45 kg/m²) with modest hypertriglyceridemia (fasting triglyceride ≥150 mg/dL (1.7 mmol/L), and <500 mg/dL (5.7 mmol/L), at screening). The study evaluates DR10624 treatment across four different dose levels. The participants will receive once-weekly subcutaneous injection of DR10624 or placebo (in a 10:2 ratio) for 12 weeks. The study will also evaluate the effects of DR10624 on serum lipids, liver fat, and body weight.

“DR10624 is a novel FIC tri-specific biotherapeutic that specifically agonizing FGF21R, GLP-1R, and GCGR. Utilizing Doer Bio’s proprietary MultipleBody^® platform technology, DR10624 is designed and engineered to exhibit balanced activity for various metabolic diseases. In our preclinical studies, DR10624 has shown outstanding potency on body weight reduction, blood lipid normalization, and liver function improvement.” said Yanshan Huang, Ph.D., founder and Chief Executive Officer of Doer Bio.

“We’re excited to announce the successful completion of patient enrollment for our Phase 1b/2a clinical trial of DR10624 in New Zealand. This achievement marks an important milestone in our clinical translation of DR10624 globally. We anticipate reporting the trial results in early 2025. There is a growing unmet medical need for patients suffering from obesity and hypertriglyceridemia. We look forward to developing DR10624 as a potential treatment for patients struggling with metabolic dysfunction.” commented Yongliang Fang, Ph.D., Chief Operating Officer of Doer Bio.

More information about the Phase 1b/2a clinical trial is available at clinicaltrials.gov (NCT05378893)

About Doer Bio

Zhejiang Doer Biologics Co., Ltd. (“Doer Bio”) is a clinical stage biopharmaceutical company that focuses on the discovery and development of multi-domain based multi-specific biotherapeutics to address unmet medical need in the field of metabolic diseases and cancers.

Doer Bio has developed multiple proprietary platform technologies, including xLONGylation^®, MultiBody^®, AccuBody^®, and SMART-VHHBody.

For more information about Doer Bio, please visit www.doerbio.com.

CONTACT: bd@doerbio.com

Source: Zhejiang Doer Biologics Co., Ltd.

Source

BANGKOK, July 5, 2024 /PRNewswire/ — realme, the world’s fastest-growing smartphone brand, today unveiled its highly anticipated ultra clear camera with AI, the realme 13 Pro Series, at the realme AI Imaging Media Preview Event in Bangkok.

Themed “The Future is Here: AI is Revolutionizing Mobile Imaging”, the media event saw industry leaders and experts come together to explore the transformative impact of AI on mobile imaging technology. Guests included Sven-Olaf Steinke, General Manager of Certification at TÜV Rheinland Greater China, who presented TÜV Rheinland’s latest insights on the innovation of mobile photography, and Toshimitsu Kurosaka, Vice President of Sony Semiconductor Solutions (Shanghai) Limited, who announced a new collaboration between Sony and realme via video presentation.

Through the collaboration between realme and Sony, the realme 13 Pro Series will see the debut of Sony’s LYT-701 sensor, promising exciting advancements in imaging experiences further empowered by realme’s industry-leading AI Photography Architecture, HYPERIMAGE+.

Revolutionizing Mobile Photography with AI

“We stand at the cusp of a revolution in mobile photography,” said Francis Wong, Head of Product Marketing at realme. “For years, the smartphone industry has been competing in a race to outdo each other in terms of imaging hardware — megapixels, sensors sizes, and lens technology. While smartphones continue to provide users with increasing flexibility and control over their shots, advancements in optical solutions have reached a limit. The future is not about hardware alone. AI is the new battlefield where the future of mobile photography will be decided.”

Marking the latest achievement in its AI innovation, realme has developed HYPERIMAGE+, the industry’s first AI photography architecture, featuring a three-layer architecture that consists of flagship optics, on-device AI imaging algorithms, and cloud-based AI image editing.

As the base layer of HYPERIMAGE+, cutting-edge optics consisting of multiple lenses, periscope lenses, and large sensors, form the foundation for advanced photography solutions capable of capturing high-quality image. Building upon this, AI imaging algorithms and AI image editing further process image data to enhance the visual quality of photo and video content. The new comprehensive approach takes mobile photography to new heights, enabling users to enjoy ultra clear camera with AI from the convenience of their smartphone.

Reconstructing Portrait Aesthetics with the realme 13 Pro Series

Powered by the HYPERIMAGE+ architecture, the realme 13 Pro Series, positioned as the Ultra Clear Camera with AI, boasts first-class optics and cutting-edge AI capabilities that together promise to deliver an experience on par with professional DSLR cameras. The realme 13 Pro+ features a dual main camera system, a 50MP OIS main camera with the industry-first Sony LYT-701, and a 50MP periscope telephoto camera with the Sony LYT-600, supporting 3x optical zoom. The advanced system enables the phones to deliver exceptional image quality in a wide range of scenarios, from low-light settings to stunning portraits.

“This collaboration is about more than just technology, it’s about empowering everyone to capture and share their world in ways never before imagined,” said Toshimitsu Kurosaka, Vice President of Sony Semiconductor Solutions (Shanghai) Limited.

By bringing AI capabilities to image processing in the RAW domain, realme’s AI HyperRAW Algorithm significantly boosts image clarity and dynamic range to capture authentic light and shadow with true-to-life results. The realme 13 Pro Series also features a series of advanced functions, including AI Pure Bokeh, AI Natural Skin Tone, and AI Ultra Clarity, which set a new benchmark for portrait photography. With AI Pure Bokeh, the camera is able to accurately identify foreground, midground, and background elements in a scene, as well as the subject being photographed, which is then used to perform pixel-level segmentation of objects and apply targeted algorithmic optimizations and processing to creating realistic cinematic portraits in seconds. AI Natural Skin Tone can enhance the natural appearance of various skin tones using on-device AI processing, while the cloud-based AI image editing feature AI Ultra Clarity can significantly enhance low resolution photos to deliver stunning quality images that overcome the physical constraints of the underlying camera hardware.

Ahead of its upcoming launch, the realme 13 Pro+ has also received the High Resolution Camera Certification by international independent third-party testing, inspection, and certification organization, TÜV Rheinland certification.

“No matter how mobile imaging evolves, clarity will always be the foundation,” said Sven-Olaf Steinke, General Manager of Certification at TÜV Rheinland Greater China. “From capturing the subtle glow of dawn and the soft light of streetlamps, to shooting intense sunlight in nature, the realme 13 Pro+ ensures exceptional image clarity in virtually any lighting environment.”

Underscoring realme’s commitment to popularizing AI and empowering young users to capture their world in a whole new way, the realme 13 Pro Series is scheduled to launch in India soon. Further details will be announced at the official launch event in India.

About realme

realme is a global consumer technology company disrupting the smartphone market by making cutting-edge technologies more accessible. It provides a range of smartphones and lifestyle technology devices with premium specs, quality, and trend-setting designs to young consumers. Established by Sky Li in 2018, realme has become one of the top 5 smartphone players in 30 markets globally in just three years, and realme has entered multiple markets worldwide, including China and Southeast Asia, South Asia, Europe, the Middle East, Latin America, and Africa, and has a global user base of over 200 million. 2024 is the year of rebranding for realme with its new slogan, “Make it real.” Under the new brand spirit, realme will focus more on young users than before and bring real, clear, and tangible benefits to their lives. For more information, please visit www.realme.com.

Contact: realmepr@realme.com

Source

TOKYO, July 5, 2024 /PRNewswire/ — Aladdin X Inc. a subsidiary of the award-winning projector and laser projector brand XGIMI, launched the ‘[Summer Version] Special Skin Expansion Pack’ in Japan on June 28th. This new pack, now available globally, allows players to enjoy customizing the game interface by combining various parts on Nintendo Switch™.

Starting June 28th, we are offering a series of free skins that allow players to customize with favorite combination at no cost. Additionally, we have released four paid skins, each inspired by a delightful summer theme: ‘Sunset Beach’, ‘Sunflower Farm’, ‘Summer Holiday’ and ‘Fireworks display’.

These paid skins include multiple customizable parts (background, Poppy, box, and dressing up your own watermelon), allowing players to create a unique design. We hope you enjoy this new feature.

We are thrilled to announce that the total number of downloads for Suika Game across Nintendo Switch, iOS, and Android has exceeded 10 million. We remain dedicated to enhancing the gaming experience for all players, and we appreciate every of your continued support.

Suika Game – Free skins

Customize the combination of the game interface including, background, box, Poppy and more to your favorite combinations at no cost.

Suika Game – [Summer Version] Special Skins Expansion Pack (Paid)

We offer a collection of four summer-themed skins: ‘Sunset Beach’, ‘Sunflower Farm’, ‘Summer Holiday’ and ‘Fireworks display’.
The [Summer Version] Special Skins Expansion Pack, which contains all four skins, is now available on the Nintendo Switch eShop worldwide.
Price: 350 JPY / 4.19 USD / 4,19 EUR / 3,500 KRW / 21 HKD

Individual purchase options:

Sunset Beach: A summer sunset beach theme with 8 interchangeable fruit parts, a newly designed Poppy and box, and a tropical background skin.
Price: 100 JPY / 1.19 USD / 1,19 EUR / 1000 KRW / 6 HKD

Sunflower Farm: A sunflower farm theme with 8 interchangeable fruit parts, a newly designed Poppy and box, and a sunflower farm background skin.
Price:  100 JPY / 1.19 USD / 1,19 EUR / 1000 KRW / 6 HKD

Summer Holiday: A summer holiday theme with 8 interchangeable fruit parts, a newly designed Poppy and box, and a traditional Japanese garden background skin.
Price: 100 JPY / 1.19 USD / 1,19 EUR / 1000 KRW / 6 HKD

Fireworks display: A fireworks display theme with 14 interchangeable fruit parts, a newly designed Poppy and box, an animated fireworks festival-style skin, an animated firework effect game start interface, limited BGM inspired by summer festivals, and sound effects that play every time the fruit evolves.
Price: 150 JPY / 1.79 USD / 1,79 EUR / 1500 KRW / 9 HKD

* Nintendo Switch is a trademark of Nintendo.

About Suika Game

Suika Game is a puzzle game where players group fruits of the same type and gradually evolve them into larger fruits, with the highest-level being a watermelon.
Copyright: ©︎ 2021 Aladdin X Inc
Official Website: https://www.aladdinx.jp/pages/suika-game
Official X: https://twitter.com/SuikaGame_jp 

About XGIMI

XGIMI Technology Co., Ltd (688696.SH), established in 2013, is a global leading brand in projectors and laser projectors, integrates design, R&D, manufacturing, sales, and service. Cooperating with well-known partners like Google, Harman Kardon, and Texas Instruments, XGIMI strives to create all-in-one entertainment products and continuously refine them with a user-centric approach. In 2023, XGIMI ranked first in the global home projector market in terms of shipments.

Additional information is available at: https://www.xgimi.com/

Source

• Peanuts, almonds and walnuts are consumed the most among Gen Z in Latin America
• 96% snack between meals, yogurt, dairy products, and fresh fruits being common choices
• Taste and health benefits are the primary drivers for consuming nuts and dried fruits
• INC’s NutTunes campaign set to encourage nut and dried fruit consumption through Spotify

BARCELONA, Spain, July 4, 2024 /PRNewswire/ — The International Nut and Dried Fruit Council (INC), conducted an extensive study on Latin America’s Gen Z dietary preferences, focusing on their consumption of nuts and dried fruits.

Nut Tunes: Feeds Your Vibe! Discover the Album on Spotify!

Generation Z prioritizes foods offering essential nutrients, plant-based protein, energy, vitamins, and fiber. The study showed that nuts and dried fruits are valued by Gen Z for their health benefits, including digestive health, heart health, and immune system support. Despite these benefits, Gen Z’s consumption of nuts and dried fruits shows room for growth.

The study surveyed 2000 respondents across Argentina, Brazil, Chile, and Mexico, revealing high awareness of nuts, especially peanuts (99%), almonds (97%), and walnuts (94%). Dried fruits like raisins (96%) and prunes (88%) are also well-known but less so.

Although there are slight nuances across countries, peanuts, almonds, and walnuts are the most consumed nuts by Gen Z followed by cashews, hazelnuts and pistachios. While raisins, dried cranberries, and prunes lead in dried fruits. Many respondents cited taste, price, and lack of information as barriers to regular consumption. Known as the “snacking generation,” 96% of Gen Z reported snacking between meals, preferring yogurt, dairy products, and fresh fruits. Nuts and dried fruits are popular but rank lower in preference.

To boost the appeal of nuts and dried fruits, INC recommends focusing on their uses and health benefits in marketing campaigns. To capture the attention of the target audience, INC has launched NutTunes, a series of captivating videos featuring 3D animation and AI technology. In these videos, nuts and dried fruits come to life and sing about their health benefits. The campaign will be promoted on social media, with tailored content for each market. Additionally, “The NutTunes” playlist is available on Spotify, providing an engaging way to connect with the audeince.

Understanding Gen Z’s preferences and attitudes is essential for businesses. By addressing barriers and emphasizing consumption drivers, INC aims to support healthier dietary choices through nut and dried fruit consumption among Gen Z in Latin America.

Source

ROCKVILLE, Md. and SUZHOU, China, July 4, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to the Exclusive Option Agreement with Takeda for the third-generation BCR-ABL inhibitor olverembatinib (HQP1351), Ascentage Pharma has received the US$100 million option payment called for by the Exclusive Option Agreement.

On June 14, 2024, Ascentage Pharma and Takeda entered into an Exclusive Option Agreement that granted Takeda an exclusive option to enter into an exclusive license agreement for olverembatinib. The Exclusive Option Agreement calls for Ascentage Pharma to receive an option payment of US$100 million and provides for Ascentage Pharma to be eligible for an option exercise fee and additional potential milestone payments of up to approximately US$1.2 billion and double-digit royalties on annual sales.

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a fully integrated global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK.

Ascentage Pharma has built a pipeline of 9 clinical-stage drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation TKIs. Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 clinical trials, including 6 global registrational Phase III studies, in the US, Australia, Europe, and China.

Olverembatinib, the company’s first lead asset developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company’s first approved product in China, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug had been included into the China National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted Orphan Drug Designations (ODDs) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU.

To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company’s investigational drug candidates. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous leading biotechnology and pharmaceutical companies such as Takeda, AstraZeneca, Merck, Pfizer and Innovent; and research and development relationships with leading research institutions such as Dana-Farber Cancer Institute, Mayo Clinic, MD Anderson Cancer Center, National Cancer Institute and the University of Michigan.

The company has built a talented team with global experience in the discovery and development of innovative drugs and is setting up its world-class commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions and expectations or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions and expectations may alter in light of future development.

Source